X4制药 XFOR 深 沪
已收盘 08-28 16:00:00 美东时间
4.04
-0.190
-4.49%
华盛通- 最 高4.23
- 今 开4.22
- 成交量 35.64万股
- 最 低 4.00
- 昨 收 4.23
- 总市值 4.01亿
- 52周最高 4.83
- 市盈率 静 --
- 换手率 0.36%
- 52周最低 2.80
- 委 比 -84.39%
- 总股本 9914.67万
- 历史最高 717.90
- 量 比 0.55
- 振 幅 5.44%
- 历史最低 2.83
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Airsculpt Technologies Inc (NASDAQ:AIRS) fell sharply in pre-market trading following second-quarter results. AirSculpt Technologies posted second-quarter adjusted earnings of 1 cent per share, ...
08-10 20:02
X4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
X4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
08-08 00:04
X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 96.25 percent increase over losses of $(3.47) per share from the same period last year. The company reported quarterly sales of $8.806 mill...
08-07 05:22
X4 Pharmaceuticals 2026年第二季度财报：许可收入推动营收增至880.6万美元
X4 Pharmaceuticals 2026年第二季度营收880.6万美元，每股亏损0.13美元，净亏损收窄至1615.7万美元。许可收入增长和费用下降推动改善，4WARD三期试验执行仍是后续重点。
08-06 21:06
美股大行评级 | 潜在涨幅98.68%！DA Davidson上调Almonty Industries目标价至33美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持Almonty Industries"买入"评级，目标价从25美元升至33美元；Stifel：维持Nurix Therapeutics"买入"评级，目标价从34美元升至40美元
07-13 10:13
Wells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11
Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight rating and announces Price Target of $11.
07-10 20:21
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
X4 Pharmaceuticals announced the appointment of Kelly Gold to its Board of Directors effective July 1, 2026. Ms. Gold, an independent director and member of the Audit Committee, brings extensive financial and biotech expertise. She currently serves as CFO at CAMP4 Therapeutics and previously held senior roles at Biogen and Deutsche Bank. Gold holds degrees in Biochemistry, Mechanical Engineering, and an MBA from MIT. X4 focuses on developing ther...
07-01 11:00
美股大行评级 | 潜在涨幅43%，慧与获11家大行集体上调目标价；最高300美元，Credo获9家大行集体上调目标价
今日重点评级关注：Ascendiant Capital：维持Genasys"买入"评级，目标价从5.5美元升至6美元；Citizens：维持Abivax"跑赢大市"评级，目标价从131美元升至187美元
06-03 11:17
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
X4 Pharmaceuticals announced that its management will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 3:45 p.m. ET. A live and archived webcast will be available on the company's website under the Investors section. X4 is focused on improving lives of people with rare hematology diseases and has developed mavorixafor, an approved therapy for WHIM syndrome. The company is currently conducting a Phase 3 clinical trial...
05-27 11:00
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
